

2

Docket No. GJE-70
Serial No. 09/868,352In the Claims

Claims 1-30 (Cancelled)

Claim 31 (Currently amended): A method for the treatment of a condition associated with bacterial Group B Streptococcal infection, wherein said method comprises administering to a patient in need of such treatment; an effective amount of a peptide encoded by a polynucleotide sequence; wherein said polynucleotide sequence comprises SEQ ID NO:22, or a homologue or functional fragment thereof; wherein said homologue is obtainable from a Group B Streptococcus and has at least 60% sequence similarity to SEQ ID NO:22 comprising the amino acid sequence of SEQ ID NO:23, or an immunogenic portion thereof, wherein the immunogenic portion elicits a protective immune response against Group B Streptococcus, and wherein the immune response recognizes the full-length amino acid sequence of SEQ ID NO:23.

Claim 32 (Cancelled)

Claim 33 (Previously added): The method according to claim 31, wherein said peptide comprises the amino acid sequence of SEQ ID NO:23.

Claim 34 (Cancelled)

Claim 35 (Previously added): The method according to claim 31, wherein the infection is a local infection.

Claim 36 (Previously added): The method according to claim 31, wherein the infection is a urinary tract infection.

J:\GJI370\Amend-Resp\Resp AF.doc\DNB\inv

3

Docket No. GJE-70
Serial No. 09/868,352

Claim 37 (Currently amended): A method for the prevention of a condition associated with bacterial Group B Streptococcal infection, wherein said method comprises administering to a patient in need of such prevention; an effective amount of a peptide encoded by a polynucleotide sequence; wherein said polynucleotide sequence comprises SEQ ID NO:22; or a homologue or functional fragment thereof; wherein said homologue is obtainable from a Group B Streptococcus and has at least 60% sequence similarity to SEQ ID NO:22 comprising the amino acid sequence of SEQ ID NO:23; or an immunogenic portion thereof, wherein the immunogenic portion elicits a protective immune response against Group B Streptococcus, and wherein the immune response recognizes the full-length amino acid sequence of SEQ ID NO:23.

Claim 38 (Cancelled)

Claim 39 (Previously added): The method according to claim 37, wherein said peptide comprises the amino acid sequence of SEQ ID NO:23.

Claim 40 (Cancelled)

Claim 41 (Previously added): The method according to claim 37, wherein the infection is a local infection.

Claim 42 (Previously added): The method according to claim 37, wherein the infection is a urinary tract infection.

J:\GJE\70\Amend-Resp\Resp AF.doc\DNB\mv

3

Docket No. GJE-70
Serial No. 09/868,352In the Claims

Claims 1-30 (Cancelled)

1
Claim ~~31~~ (Currently amended): A method for the treatment of a condition associated with Group B Streptococcal infection caused by Streptococcus agalactiae, wherein said method comprises administering to a patient an effective amount of a an isolated peptide comprising the amino acid sequence of SEQ ID NO:23, or an immunogenic portion thereof, wherein the immunogenic portion elicits a protective immune response against Group B Streptococcus, and wherein the immune response recognizes the full-length amino acid sequence of SEQ ID NO:23 or an isolated peptide comprising the immunogenic portion of SEQ ID NO: 23, wherein said immunogenic portion induces an immune response and selectively binds to anti-Streptococcus agalactiae antibody specific for SEQ ID NO: 23.

Claim 32 (Cancelled)

2
Claim ~~33~~ (Currently amended): The method according to claim ~~31~~, wherein said peptide comprises comprising the amino acid sequence of SEQ ID NO:23 is administered to the patient.

Claim 34 (Cancelled)

3
Claim ~~35~~ (Previously added): The method according to claim ~~31~~, wherein the infection is a local infection.

4
Claim ~~36~~ (Previously added): The method according to claim ~~31~~, wherein the infection is a urinary tract infection.

5
Claim ~~37~~ (Currently amended): A method for the prevention of a condition associated with Group B Streptococcal infection caused by Streptococcus agalactiae, wherein said method comprises

J:\GJE\70\Amend-Resp\SuppAmend\AF.doc/DND/mv

4

Docket No. GJE-70
Serial No. 09/868,352

administering to a patient an effective amount of a an isolated peptide comprising the amino acid sequence of SEQ ID NO:23, or an immunogenic portion thereof, wherein the immunogenic portion elicits a protective immune response against Group B Streptococcus, and wherein the immune response recognizes the full-length amino acid sequence of SEQ ID NO:23 or an isolated peptide comprising the immunogenic portion of SEQ ID NO: 23, wherein said immunogenic portion induces an immune response and selectively binds to anti-Streptococcus agalactiae antibody specific for SEQ ID NO: 23.

Claim 38 (Cancelled)

⁶ Claim ~~39~~⁵ (Currently amended): The method according to claim ~~37~~⁵, wherein said peptide comprises comprising the amino acid sequence of SEQ ID NO:23 is administered to the patient.

Claim 40 (Cancelled)

⁷ Claim ~~41~~⁵ (Previously added): The method according to claim ~~37~~⁵, wherein the infection is a local infection.

⁸ Claim ~~42~~⁵ (Previously added): The method according to claim ~~37~~⁵, wherein the infection is a urinary tract infection.

J:\GJE\70\Amend-Resp\SuppAmendAF.doc\DND/mv